Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Spijkers, Léon J A ^a   Janssen, Ben J A ^b   Nelissen, Jelly ^b   Meens, Merlijn J P M T ^b   Wijesinghe, Dayanjan ^c   Chalfant, Charles E ^c   de Mey, Jo G R ^b   Alewijnse, Astrid E ^a   Peters, Stephan L M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CERAMIDE; CYCLOOXYGENASE 1; HYDRALAZINE; LOSARTAN; PHOSPHOLIPASE; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; THROMBOXANE A2; VASODILATOR AGENT; PHOSPHOLIPASE A2 GROUP VI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MYOGRAPHY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT; ANIMAL; BLOOD; BLOOD PRESSURE; BLOOD VESSEL; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD VESSELS; CAROTID ARTERIES; CERAMIDES; ENDOTHELIUM, VASCULAR; GROUP VI PHOSPHOLIPASES A2; HYDRALAZINE; LOSARTAN; MALE; RATS; RATS, INBRED SHR; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; VASOCONSTRICTION;

EID: 83455205960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029222     Document Type: Article

References (31)

1. Chatterjee S, (1998) Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 18: 1523-1533.
2. Gulbins E, (2003) Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol Res 47: 393-399.
3. Pyne S, Pyne NJ, (2000) Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 349: 385-402.
4. Saba JD, Hla T, (2004) Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 94: 724-734.
5. Mulders AC, Hendriks-Balk MC, Mathy MJ, Michel MC, Alewijnse AE, et al. (2006) Sphingosine kinase-dependent activation of endothelial nitric oxide synthase by angiotensin II. Arterioscler Thromb Vasc Biol 26: 2043-2048.
6. Dantas AP, Igarashi J, Michel T, (2003) Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 284: H2045-H2052.
7. Mulders AC, Mathy MJ, Meyer zu Heringdorf D, ter Braak M, Hajji N, et al. (2009) Activation of sphingosine kinase by muscarinic receptors enhances NO-mediated and attenuates EDHF-mediated vasorelaxation. Basic Res Cardiol 104: 50-59.
8. Fenger M, Linneberg A, Jorgensen T, Madsbad S, Sobye K, et al. (2011) Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension. BMC Genet 12: 44.
9. Yogi A, Callera GE, Aranha AB, Antunes TT, Graham D, et al. (2011) Sphingosine-1-phosphate-induced inflammation involves receptor tyrosine kinase transactivation in vascular cells: upregulation in hypertension. Hypertension 57: 809-818.
10. Spijkers LJ, van den Akker RF, Janssen BJ, Debets JJ, De Mey JG, et al. (2011) Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide. PLoS ONE 6 (7): e21817 doi:10.1371/journal.pone.0021817.
11. Merrill AH Jr, Sullards MC, Allegood JC, Kelly S, Wang E, (2005) Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36: 207-224.
12. Wijesinghe DS, Allegood JC, Gentile LB, Fox TE, Kester M, et al. (2010) Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. J Lipid Res 51: 641-651.
13. Demirci B, McKeown PP, Bayraktutan U, (2005) Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. J Hypertens 23: 2219-2227.
14. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG, (2001) Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 281: H2337-H2365.
15. Czarny M, Schnitzer JE, (2004) Neutral sphingomyelinase inhibitor scyphostatin prevents and ceramide mimics mechanotransduction in vascular endothelium. Am J Physiol Heart Circ Physiol 287: H1344-H1352.
16. Dohi Y, Criscione L, Pfeiffer K, Luscher TF, (1994) Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 24: 372-379.
17. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Luscher TF, (1994) Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 89: 2212-2218.
18. Akiba S, Mizunaga S, Kume K, Hayama M, Sato T, (1999) Involvement of group VI Ca2+-independent phospholipase A2 in protein kinase C-dependent arachidonic acid liberation in zymosan-stimulated macrophage-like P388D1 cells. J Biol Chem 274: 19906-19912.
19. Xie Z, Gong MC, Su W, Xie D, Turk J, et al. (2010) Role of calcium-independent phospholipase A2beta in high glucose-induced activation of RhoA, Rho kinase, and CPI-17 in cultured vascular smooth muscle cells and vascular smooth muscle hypercontractility in diabetic animals. J Biol Chem 285: 8628-8638.
20. Xie Z, Gong MC, Su W, Turk J, Guo Z, (2007) Group VIA phospholipase A2 (iPLA2beta) participates in angiotensin II-induced transcriptional up-regulation of regulator of g-protein signaling-2 in vascular smooth muscle cells. J Biol Chem 2007 282: 25278-25289.
21. Li P, Ferrario CM, Brosnihan KB, (1998) Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 32: 198-205.
22. Aulakh GK, Sodhi RK, Singh M, (2007) An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci 81: 615-639.
23. Matsumoto T, Ishida K, Nakayama N, Taguchi K, Kobayashi T, et al. (2010) Mechanisms underlying the losartan treatment-induced improvement in the endothelial dysfunction seen in mesenteric arteries from type 2 diabetic rats. Pharmacol Res 62: 271-281.
24. Brinkmann V, (2009) FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158: 1173-1182.
25. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, et al. (2005) Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 11: 491-498.
26. Hu ZP, Wang BN, Qian HY, Zhou Q, Wei W, et al. (2010) Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients. Int Heart J 51: 252-258.
27. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R, (2002) Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40: 505-510.
28. Ruschitzka F, Noll G, Luscher TF, (1999) Angiotensin converting enzyme inhibitors and vascular protection in hypertension. J Cardiovasc Pharmacol 34 (Suppl 1): S3-12.
29. Taddei S, Virdis A, Ghiadoni L, Salvetti A, (1998) The role of endothelium in human hypertension. Curr Opin Nephrol Hypertens 7: 203-209.
30. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, et al. (2009) Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58: 337-343.
31. Boini KM, Zhang C, Xia M, Poklis JL, Li PL, (2010) Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther 334: 839-846.